<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Blizard Institute of Cell and Molecular</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5B1BC4D3-DB25-42AE-A1E3-F5FE202F977D"><gtr:id>5B1BC4D3-DB25-42AE-A1E3-F5FE202F977D</gtr:id><gtr:firstName>Gavin</gtr:firstName><gtr:surname>Giovannoni</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EA541409-8246-4C18-9E08-5E7CE24C501B"><gtr:id>EA541409-8246-4C18-9E08-5E7CE24C501B</gtr:id><gtr:firstName>Dorothy</gtr:firstName><gtr:surname>Crawford</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D1FC9691-3AF3-47BE-96DF-40E94E1E2473"><gtr:id>D1FC9691-3AF3-47BE-96DF-40E94E1E2473</gtr:id><gtr:firstName>A</gtr:firstName><gtr:surname>Madrigal</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/031603EF-9C4C-4FB8-BB12-66E1D99E0924"><gtr:id>031603EF-9C4C-4FB8-BB12-66E1D99E0924</gtr:id><gtr:firstName>Ann-Margaret</gtr:firstName><gtr:surname>Little</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C1B59EE0-2FB9-4458-A7B2-08B1D23D5681"><gtr:id>C1B59EE0-2FB9-4458-A7B2-08B1D23D5681</gtr:id><gtr:firstName>Judith</gtr:firstName><gtr:surname>Breuer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0908E29E-6C17-463E-9A8C-303E70B13032"><gtr:id>0908E29E-6C17-463E-9A8C-303E70B13032</gtr:id><gtr:firstName>George</gtr:firstName><gtr:surname>Ebers</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801975"><gtr:id>B92DC1AB-B62F-4C21-B9E8-2B79A3DE59EF</gtr:id><gtr:title>Epstein-Barr virus infection in multiple sclerosis and control subjects: an HLA association study</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801975</gtr:grantReference><gtr:abstractText>Although MS is believed to be an autoimmune disease in which the body?s own immune system attacks the myelin sheaths in the central nervous system (CNS), a specific infectious cause for MS has not been definitively excluded. Several studies have demonstrated a link between the virus which causes glandular fever and MS. This virus is called Epstein-Barr Virus (EBV), which is a member of the herpes group of viruses. EBV, like the other herpes viruses, has the ability to lie dormant or latent in the body and to reactivate itself intermittently. These episodes of EBV reactivation generally do not cause symptoms, but in people with MS they may trigger clinical attacks. Almost all people with MS are infected with EBV compared to only 9 out of 10 people in the general population. Although this difference may seem small it is highly significant and a consistent finding across numerous studies. People who have symptoms (i.e. infectious mononucleosis, often called glandular fever) as a result of their initial EBV infection have an increased risk of developing MS in the future compared to people who do not experience symptoms with their initial EBV infection. Scientists who study the immune system have demonstrated that white blood cells with the potential to attack myelin can also be activated by EBV. People with MS have evidence of ongoing or recent reactivation of EBV in their blood compared to normal control subjects. More recently there has been a study demonstrating that reactivation of EBV in people with MS is closely linked to onset of MS attacks or relapses. Overall, the above evidence suggests that EBV infection and the intermittent reactivation of EBV infection are linked to MS disease activity. We want to study: (1) sibling pairs with MS to see if there are any differences between sibling pairs with and without MS in relation to the rate of EBV infection; (2) healthy controls to see if people who remain EBV negative and are resistant to developing MS because they lack genes that make them susceptible to developing MS; (3) establish whether or not adults who develop IM are more likely to carry genes associated with MS; (4) establish whether or not people with MS are more likely to be carry genes, which have been shown to predispose to glandular fever or infectious mononucleosis.</gtr:abstractText><gtr:technicalSummary>Although MS is a complex disease due to interactions between genes and environmental factors, one pivotal factor may be so critical that if it can be removed or neutralised MS may be become a preventable disease. Epstein Barr virus (EBV) infection may be this pivotal factor. Virtually all subjects with MS ( 99%) are infected with EBV compared to only ~90% of control subjects. The important corollary is that MS is very rare in subjects who are not infected with EBV. A tantalizing hypothesis is that if you could prevent somebody being infected with EBV could you prevent them from developing MS? There is growing body of literature suggesting that the association between EBV and MS may be causative. We therefore plan to (1) investigate seroprevalence rates between concordant and discordant MS sibling pairs, (2) investigate whether or not EBV seronegativity in normal control subjects is associated with HLA haplotypes that are protective for MS, (3) establish whether or not adults who develop IM are more likely to carry extended HLA haplotypes associated with MS genetic susceptibility compared to subjects with asymptomatic EBV seroconversion and (4) establish whether or not people with MS are more likely to be carry HLA haplotypes, which have been shown to predispose to IM. This study will also investigate the humoral response to a panel of control viruses, which provides an opportunity of exploring HLA associations with other common viral infections, interactions between these viruses and EBV, and whether or not EBV infection affects B-cell memory responses.</gtr:technicalSummary><gtr:fund><gtr:end>2012-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>484197</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>multiple sclerosis blog</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>24F2713E-BEEC-47E8-8AFE-606060C2F514</gtr:id><gtr:impact>A daily blog detailing the latest in MS research. 
&amp;gt;200,000 page view per month
&amp;gt;1.2M slideshare views per month

This blog is now one of the most read blogs in MS across the world.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://multiple-sclerosis-research.blogspot.com/</gtr:url><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MS Research Day 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DDB10D63-F5B8-4E03-A6D3-5F7B18623002</gtr:id><gtr:impact>300 MS patients and their relatives attended a day of talks on MS research taking place at our institute

The interest was substantial and we are holding another research day in 2012.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://multiple-sclerosis-research.blogspot.com/2012/02/research-day-prof-g.html</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Day 2010 for Patients with MS</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5B3E06CF-5FB0-4345-B5C0-265F54FB660E</gtr:id><gtr:impact>The results of this study and on-going work in my lab were presented as part of a research day for patients with multiple sclerosis and their families. Over 100 patients and family members attended.

The interest and enthusiasm for the day was high and we will therefore make this an annual event</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>https://www.youtube.com/user/linzkeith#grid/user/C5BBC29967E2E7E9</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MS Research Day 2012</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F857FA77-37E0-400C-B4E0-DC85B5EF53CF</gtr:id><gtr:impact>Day explaining research projects in lay terms for MS patients and their families

Continued interest has led us to organising a research day for 2013</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/34686EF3-F47C-4A05-9D8E-B8ED20322BD8"><gtr:id>34686EF3-F47C-4A05-9D8E-B8ED20322BD8</gtr:id><gtr:title>Vitamin D: a link between Epstein-Barr virus and multiple sclerosis development?</gtr:title><gtr:parentPublicationTitle>Expert review of neurotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1473-7175</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6A67A44E-2209-4EFC-B657-F604E3641930"><gtr:id>6A67A44E-2209-4EFC-B657-F604E3641930</gtr:id><gtr:title>Epstein-Barr virus, latitude and multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B640137C-3500-493A-AB6F-E770352D2158"><gtr:id>B640137C-3500-493A-AB6F-E770352D2158</gtr:id><gtr:title>Sex ratio of infectious mononucleosis and possible relevance to multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b76c8aca5550da4a9dad29ded472960"><gtr:id>9b76c8aca5550da4a9dad29ded472960</gtr:id><gtr:otherNames>Ramagopalan SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E420EF0D-1222-408F-B50B-34615B4A2FA3"><gtr:id>E420EF0D-1222-408F-B50B-34615B4A2FA3</gtr:id><gtr:title>Vitamin D receptor binding, chromatin states and association with multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/18F604C9-CCEF-4D68-BAFD-988B4D92EA31"><gtr:id>18F604C9-CCEF-4D68-BAFD-988B4D92EA31</gtr:id><gtr:title>The evidence for a role of B cells in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C5273EA7-38FE-4DD9-A396-21D8F21F9843"><gtr:id>C5273EA7-38FE-4DD9-A396-21D8F21F9843</gtr:id><gtr:title>Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b76c8aca5550da4a9dad29ded472960"><gtr:id>9b76c8aca5550da4a9dad29ded472960</gtr:id><gtr:otherNames>Ramagopalan SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1C2CC8BF-3B7B-4CF9-B389-831D884D48E0"><gtr:id>1C2CC8BF-3B7B-4CF9-B389-831D884D48E0</gtr:id><gtr:title>An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/32940939798776e174a016529546b916"><gtr:id>32940939798776e174a016529546b916</gtr:id><gtr:otherNames>Handel AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7D832295-71D9-45BD-BF2E-380C9CCD35B5"><gtr:id>7D832295-71D9-45BD-BF2E-380C9CCD35B5</gtr:id><gtr:title>Guthrie card methylomics identifies temporally stable epialleles that are present at birth in humans.</gtr:title><gtr:parentPublicationTitle>Genome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aaeb29cc1c94a3d6b48a6426ed307e09"><gtr:id>aaeb29cc1c94a3d6b48a6426ed307e09</gtr:id><gtr:otherNames>Beyan H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1088-9051</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8B93DAF2-E91E-43D5-845D-B646E32297B4"><gtr:id>8B93DAF2-E91E-43D5-845D-B646E32297B4</gtr:id><gtr:title>Multiple sclerosis: risk factors, prodromes, and potential causal pathways.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b76c8aca5550da4a9dad29ded472960"><gtr:id>9b76c8aca5550da4a9dad29ded472960</gtr:id><gtr:otherNames>Ramagopalan SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A8080C7C-69D1-4CA7-8435-824C06AC5C54"><gtr:id>A8080C7C-69D1-4CA7-8435-824C06AC5C54</gtr:id><gtr:title>Relationship of UV exposure to prevalence of multiple sclerosis in England.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b76c8aca5550da4a9dad29ded472960"><gtr:id>9b76c8aca5550da4a9dad29ded472960</gtr:id><gtr:otherNames>Ramagopalan SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C5CC13AA-94F1-46F2-8FB4-809C1D7CAFCC"><gtr:id>C5CC13AA-94F1-46F2-8FB4-809C1D7CAFCC</gtr:id><gtr:title>Protein-protein interaction analysis highlights additional loci of interest for multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f60749d0066cd6b191555398fff0650"><gtr:id>5f60749d0066cd6b191555398fff0650</gtr:id><gtr:otherNames>Ragnedda G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B6EF8165-D33B-47B4-9385-52E48A01BBF6"><gtr:id>B6EF8165-D33B-47B4-9385-52E48A01BBF6</gtr:id><gtr:title>Estimating the proportion of variation in susceptibility to multiple sclerosis captured by common SNPs.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c5fb3a941e77ca8f5476abcbc141ecad"><gtr:id>c5fb3a941e77ca8f5476abcbc141ecad</gtr:id><gtr:otherNames>Watson CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0D2DD812-A254-45A4-98B3-04151DE123A2"><gtr:id>0D2DD812-A254-45A4-98B3-04151DE123A2</gtr:id><gtr:title>Geography of hospital admissions for multiple sclerosis in England and comparison with the geography of hospital admissions for infectious mononucleosis: a descriptive study.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b76c8aca5550da4a9dad29ded472960"><gtr:id>9b76c8aca5550da4a9dad29ded472960</gtr:id><gtr:otherNames>Ramagopalan SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CAA7491C-31CE-4871-99B6-0D7AF7F425C2"><gtr:id>CAA7491C-31CE-4871-99B6-0D7AF7F425C2</gtr:id><gtr:title>Association of infectious mononucleosis with multiple sclerosis. A population-based study.</gtr:title><gtr:parentPublicationTitle>Neuroepidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b76c8aca5550da4a9dad29ded472960"><gtr:id>9b76c8aca5550da4a9dad29ded472960</gtr:id><gtr:otherNames>Ramagopalan SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0251-5350</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/18765257-5817-4BEE-88FB-EDB7047B5E7C"><gtr:id>18765257-5817-4BEE-88FB-EDB7047B5E7C</gtr:id><gtr:title>Next-generation sequencing in understanding complex neurological disease.</gtr:title><gtr:parentPublicationTitle>Expert review of neurotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/32940939798776e174a016529546b916"><gtr:id>32940939798776e174a016529546b916</gtr:id><gtr:otherNames>Handel AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1473-7175</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6C692826-D170-4376-A951-F6A98E4B2CD3"><gtr:id>6C692826-D170-4376-A951-F6A98E4B2CD3</gtr:id><gtr:title>Month of birth, vitamin D and risk of immune-mediated disease: a case control study.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/91EC6C4E-E643-449A-874B-DFD1F8EA8939"><gtr:id>91EC6C4E-E643-449A-874B-DFD1F8EA8939</gtr:id><gtr:title>Role of the HLA system in the association between multiple sclerosis and infectious mononucleosis.</gtr:title><gtr:parentPublicationTitle>Archives of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b76c8aca5550da4a9dad29ded472960"><gtr:id>9b76c8aca5550da4a9dad29ded472960</gtr:id><gtr:otherNames>Ramagopalan SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-9942</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2A94CA1B-2EBE-41A4-8BA9-52BE25B7BA68"><gtr:id>2A94CA1B-2EBE-41A4-8BA9-52BE25B7BA68</gtr:id><gtr:title>Human IFNAR2 deficiency: Lessons for antiviral immunity.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5706f9c76e406abe3c614f09d311abc1"><gtr:id>5706f9c76e406abe3c614f09d311abc1</gtr:id><gtr:otherNames>Duncan CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1442AA01-728C-45C0-8A77-E1F0BDC1AFF9"><gtr:id>1442AA01-728C-45C0-8A77-E1F0BDC1AFF9</gtr:id><gtr:title>Genomic regions associated with multiple sclerosis are active in B cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/256CF3A6-7179-429F-BBEC-5B65E6729913"><gtr:id>256CF3A6-7179-429F-BBEC-5B65E6729913</gtr:id><gtr:title>The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/63e5b7621621fb6aaaf3c2def012af64"><gtr:id>63e5b7621621fb6aaaf3c2def012af64</gtr:id><gtr:otherNames>Pakpoor J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801975</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>